Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.

Fasslrinner F, Arndt C, Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornhäuser M, Bachmann M.

Br J Haematol. 2019 Sep;186(5):735-740. doi: 10.1111/bjh.15975. Epub 2019 May 23.

PMID:
31119728
2.

Apoptotic mesenchymal stromal cells induce prostaglandin E2 in monocytes: implications for the monitoring of mesenchymal stromal cells activity.

Cheung TS, Galleu A, von Bonin M, Bornhäuser M, Dazzi F.

Haematologica. 2019 Mar 7. pii: haematol.2018.214767. doi: 10.3324/haematol.2018.214767. [Epub ahead of print]

3.

Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells.

Albert S, Koristka S, Gerbaulet A, Cartellieri M, Arndt C, Feldmann A, Berndt N, Loureiro LR, von Bonin M, Ehninger G, Eugster A, Bonifacio E, Bornhäuser M, Bachmann MP, Ehninger A.

J Immunol. 2019 Mar 15;202(6):1735-1746. doi: 10.4049/jimmunol.1801004. Epub 2019 Feb 6.

PMID:
30728213
4.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.

Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.

PMID:
30442503
5.

JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia-Letter.

von Bonin M, Moll K, Kramer M, Oelschlägel U, Wermke M, Röllig C, Thiede C, Ehninger G, Krämer A, Müller-Tidow C, Mitroulis I, Bornhäuser M.

Cancer Res. 2018 Nov 1;78(21):6339-6341. doi: 10.1158/0008-5472.CAN-18-0642. Epub 2018 Oct 17. No abstract available.

PMID:
30333115
6.

Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.

Teipel R, Oelschlägel U, Wetzko K, Schmiedgen M, Kramer M, Rücker-Braun E, Hölig K, von Bonin M, Heidrich K, Fuchs A, Ordemann R, Kroschinsky F, Bornhäuser M, Hütter G, Schmidt H, Ehninger G, Schetelig J, Heidenreich F.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2171-2177. doi: 10.1016/j.bbmt.2018.06.023. Epub 2018 Jun 21.

PMID:
29935214
7.

STK3 is a therapeutic target for a subset of acute myeloid leukemias.

Camgoz A, Paszkowski-Rogacz M, Satpathy S, Wermke M, Hamann MV, von Bonin M, Choudhary C, Knapp S, Buchholz F.

Oncotarget. 2018 May 22;9(39):25458-25473. doi: 10.18632/oncotarget.25238. eCollection 2018 May 22.

8.

Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Middeke JM, Kollinger F, Baldauf H, Stölzel F, Wermke M, von Bonin M, Sockel K, Link CS, Teipel R, Röllig C, Thiede C, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1947-1951. doi: 10.1016/j.bbmt.2018.05.021. Epub 2018 May 21.

9.

Hematopoietic stem cells can differentiate into restricted myeloid progenitors before cell division in mice.

Grinenko T, Eugster A, Thielecke L, Ramasz B, Krüger A, Dietz S, Glauche I, Gerbaulet A, von Bonin M, Basak O, Clevers H, Chavakis T, Wielockx B.

Nat Commun. 2018 May 15;9(1):1898. doi: 10.1038/s41467-018-04188-7.

10.

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.

Wermke M, Eckoldt J, Götze KS, Klein SA, Bug G, de Wreede LC, Kramer M, Stölzel F, von Bonin M, Schetelig J, Laniado M, Plodeck V, Hofmann WK, Ehninger G, Bornhäuser M, Wolf D, Theurl I, Platzbecker U.

Lancet Haematol. 2018 May;5(5):e201-e210. doi: 10.1016/S2352-3026(18)30036-X. Epub 2018 Apr 5.

PMID:
29628397
11.

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.

Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group.

Br J Haematol. 2019 Mar;184(5):833-836. doi: 10.1111/bjh.15181. Epub 2018 Mar 12. No abstract available.

PMID:
29528122
12.

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells.

Bachmann D, Aliperta R, Bergmann R, Feldmann A, Koristka S, Arndt C, Loff S, Welzel P, Albert S, Kegler A, Ehninger A, Cartellieri M, Ehninger G, Bornhäuser M, von Bonin M, Werner C, Pietzsch J, Steinbach J, Bachmann M.

Oncotarget. 2017 Dec 21;9(7):7487-7500. doi: 10.18632/oncotarget.23556. eCollection 2018 Jan 26.

13.

Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34⁺CD123⁺ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia.

Schmidt JR, Rücker-Braun E, Heidrich K, von Bonin M, Stölzel F, Thiede C, Middeke JM, Ehninger G, Bornhäuser M, Schetelig J, Schubert K, von Bergen M, Heidenreich F.

Proteomes. 2018 Feb 12;6(1). pii: E11. doi: 10.3390/proteomes6010011.

14.

Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.

Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, von Bonin M, Barbieri L, Halai K, Ward S, Weng L, Chakraverty R, Lombardi G, Watt FM, Orchard K, Marks DI, Apperley J, Bornhauser M, Walczak H, Bennett C, Dazzi F.

Sci Transl Med. 2017 Nov 15;9(416). pii: eaam7828. doi: 10.1126/scitranslmed.aam7828.

15.

Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.

Pishali Bejestani E, Cartellieri M, Bergmann R, Ehninger A, Loff S, Kramer M, Spehr J, Dietrich A, Feldmann A, Albert S, Wermke M, Baumann M, Krause M, Bornhäuser M, Ehninger G, Bachmann M, von Bonin M.

Oncoimmunology. 2017 Jun 20;6(10):e1342909. doi: 10.1080/2162402X.2017.1342909. eCollection 2017.

16.

Zebrafish In-Vivo Screening for Compounds Amplifying Hematopoietic Stem and Progenitor Cells: - Preclinical Validation in Human CD34+ Stem and Progenitor Cells.

Arulmozhivarman G, Kräter M, Wobus M, Friedrichs J, Bejestani EP, Müller K, Lambert K, Alexopoulou D, Dahl A, Stöter M, Bickle M, Shayegi N, Hampe J, Stölzel F, Brand M, von Bonin M, Bornhäuser M.

Sci Rep. 2017 Sep 21;7(1):12084. doi: 10.1038/s41598-017-12360-0.

17.

Neurotrophin Receptor p75NTR Regulates Immune Function of Plasmacytoid Dendritic Cells.

Bandoła J, Richter C, Ryser M, Jamal A, Ashton MP, von Bonin M, Kuhn M, Dorschner B, Alexopoulou D, Navratiel K, Roeder I, Dahl A, Hedrich CM, Bonifacio E, Brenner S, Thieme S.

Front Immunol. 2017 Aug 17;8:981. doi: 10.3389/fimmu.2017.00981. eCollection 2017.

18.

Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche.

Mitroulis I, Chen LS, Singh RP, Kourtzelis I, Economopoulou M, Kajikawa T, Troullinaki M, Ziogas A, Ruppova K, Hosur K, Maekawa T, Wang B, Subramanian P, Tonn T, Verginis P, von Bonin M, Wobus M, Bornhäuser M, Grinenko T, Di Scala M, Hidalgo A, Wielockx B, Hajishengallis G, Chavakis T.

J Clin Invest. 2017 Oct 2;127(10):3624-3639. doi: 10.1172/JCI92571. Epub 2017 Aug 28.

19.

Dynamics of epigenetic age following hematopoietic stem cell transplantation.

Stölzel F, Brosch M, Horvath S, Kramer M, Thiede C, von Bonin M, Ammerpohl O, Middeke M, Schetelig J, Ehninger G, Hampe J, Bornhäuser M.

Haematologica. 2017 Aug;102(8):e321-e323. doi: 10.3324/haematol.2016.160481. Epub 2017 May 26. No abstract available.

20.

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. Epub 2017 May 17.

21.

Abstracts of the 52nd Workshop for Pediatric Research : Frankfurt, Germany. 27-28 October 2016.

van den Bruck R, Weil PP, Ziegenhals T, Schreiner P, Juranek S, Gödde D, Vogel S, Schuster F, Orth V, Dörner J, Pembaur D, Röper M, Störkel S, Zirngibl H, Wirth S, Jenke ACW, Postberg J, Boy N, Heringer J, Haege G, Glahn EM, Hoffmann GF, Garbade SF, Burgard P, Kölker S, Chao CM, Yahya F, Moiseenko A, Shrestha A, Ahmadvand N, Quantius J, Wilhelm J, El-Agha E, Zimmer KP, Bellusci S, Staufner C, Kölker S, Prokisch H, Hoffmann GF, Seeliger S, Müller M, Hippe A, Steinkraus H, Wauer R, Lachmann B, Hofmann SR, Hedrich CM, Zierk J, Arzideh F, Haeckel R, Rascher W, Rauh M, Metzler M, Thieme S, Bandoła J, Richter C, Ryser M, Jamal A, Ashton MP, von Bonin M, Kuhn M, Hedrich CM, Bonifacio E, Berner R, Brenner S, Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Söder S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H, Bohne F, Langer D, Cencic R, Eggermann T, Zechner U, Pelletier J, Zepp F, Enklaar T, Prawitt D, Pech M, Weckmann M, Heinsen FA, Franke A, Happle C, Dittrich AM, Hansen G, Fuchs O, von Mutius E, Oliver BG, Kopp MV, Paret C, Russo A, Theruvath J, Keller B, El Malki K, Lehmann N, Wingerter A, Neu MA, Aslihan GA, Wagner W, Sommer C, Pietsch T, Seidmann L, Faber J, Schreiner F, Ackermann M, Michalik M, Rother E, Bilkei-Gorzo A, Racz I, Bindila L, Lutz B, Dötsch J, Zimmer A, Woelfle J, Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G, Stein R, Hofmann SR, Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ, Loges NT, Frommer AT, Wallmeier J, Omran H, Öner-Sieben S, Gimpfl M, Rozman J, Irmler M, Beckers J, De Angelis MH, Roscher A, Wolf E, Ensenauer R, Nemes K, Frühwald M, Hasselblatt M, Siebert R, Kordes U, Kool M, Wang H, Hardy H, Refai O, Barwick KES, Zimmerman HH, Weis J, Baple EL, Crosby AH, Cirak S, Hellmuth C, Uhl O, Standl M, Heinrich J, Thiering E, Koletzko B, Blümel L, Kerl K, Picard D, Frühwald MC, Liebau MC, Reifenberger G, Borkhardt A, Hasselblatt M, Remke M, Tews D, Wabitsch M, Fischer-Posovszky P, Westhoff MA, Nonnenmacher L, Langhans J, Schneele L, Trenkler N, Debatin KM.

Mol Cell Pediatr. 2017 May;4(Suppl 1):5. doi: 10.1186/s40348-017-0071-0. No abstract available.

22.

Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.

Büttner B, Knoth H, Kramer M, Oertel R, Seeling A, Sockel K, von Bonin M, Stölzel F, Alakel N, Platzbecker U, Röllig C, Ehninger G, Bornhäuser M, Schetelig J, Middeke JM.

Leuk Lymphoma. 2017 Dec;58(12):2865-2874. doi: 10.1080/10428194.2017.1319051. Epub 2017 May 16.

PMID:
28509593
23.

A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche.

Bray LJ, Binner M, Körner Y, von Bonin M, Bornhäuser M, Werner C.

Haematologica. 2017 Jul;102(7):1215-1226. doi: 10.3324/haematol.2016.157883. Epub 2017 Mar 30.

24.

Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology.

Tunger A, Wehner R, von Bonin M, Kühn D, Heidenreich F, Matko S, Nauerth M, Rücker-Braun E, Dietz S, Link CS, Eugster A, Odendahl M, Busch DH, Tonn T, Bonifacio E, Germeroth L, Schetelig J, Bachmann MP, Bornhäuser M, Schmitz M.

Leuk Lymphoma. 2017 May;58(5):1246-1249. doi: 10.1080/10428194.2016.1233538. Epub 2016 Nov 16. No abstract available.

PMID:
27852136
25.

Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).

Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U.

Br J Haematol. 2016 Dec;175(5):917-924. doi: 10.1111/bjh.14345. Epub 2016 Oct 7.

PMID:
27714772
26.

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.

Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, von Bonin M, Bejestani EP, Ehninger G, Bachmann MP.

Blood Cancer J. 2016 Aug 12;6(8):e458. doi: 10.1038/bcj.2016.61.

27.

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M.

Ann Hematol. 2016 Oct;95(11):1805-10. doi: 10.1007/s00277-016-2775-y. Epub 2016 Aug 10.

PMID:
27510179
28.

Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells.

Dhawan A, von Bonin M, Bray LJ, Freudenberg U, Pishali Bejestani E, Werner C, Hofbauer LC, Wobus M, Bornhäuser M.

Stem Cells. 2016 Aug;34(8):2224-35. doi: 10.1002/stem.2384. Epub 2016 May 18.

29.

Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Link CS, Teipel R, Heidenreich F, Rücker-Braun E, Schmiedgen M, Reinhardt J, Oelschlägel U, von Bonin M, Middeke JM, Muetherig A, Trautmann-Grill K, Platzbecker U, Bornhäuser M, Schetelig J.

Bone Marrow Transplant. 2016 Jun;51(6):793-8. doi: 10.1038/bmt.2015.339. Epub 2016 Jan 11.

PMID:
26752141
30.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
31.

Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.

von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, Schmitz M, Platzbecker U, Schetelig J, Bornhäuser M, von Bonin M.

Stem Cells. 2016 Feb;34(2):357-66. doi: 10.1002/stem.2224. Epub 2015 Oct 13.

32.

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.

Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, von Bonin M, Ehninger A, Bachmann J, Ehninger G, Bornhäuser M, Bachmann MP.

Blood Cancer J. 2015 Sep 18;5:e348. doi: 10.1038/bcj.2015.73.

33.

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Leukemia. 2016 Feb;30(2):261-7. doi: 10.1038/leu.2015.226. Epub 2015 Aug 18.

PMID:
26283567
34.

NFATc1 as a therapeutic target in FLT3-ITD-positive AML.

Metzelder SK, Michel C, von Bonin M, Rehberger M, Hessmann E, Inselmann S, Solovey M, Wang Y, Sohlbach K, Brendel C, Stiewe T, Charles J, Ten Haaf A, Ellenrieder V, Neubauer A, Gattenlöhner S, Bornhäuser M, Burchert A.

Leukemia. 2015 Jul;29(7):1470-7. doi: 10.1038/leu.2015.95. Epub 2015 Apr 14.

PMID:
25976987
35.

RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug.

Wermke M, Camgoz A, Paszkowski-Rogacz M, Thieme S, von Bonin M, Dahl A, Platzbecker U, Theis M, Ehninger G, Brenner S, Bornhäuser M, Buchholz F.

Blood. 2015 Jun 11;125(24):3760-8. doi: 10.1182/blood-2014-07-590646. Epub 2015 Apr 30.

36.

Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.

Theil A, Tuve S, Oelschlägel U, Maiwald A, Döhler D, Oßmann D, Zenkel A, Wilhelm C, Middeke JM, Shayegi N, Trautmann-Grill K, von Bonin M, Platzbecker U, Ehninger G, Bonifacio E, Bornhäuser M.

Cytotherapy. 2015 Apr;17(4):473-86. doi: 10.1016/j.jcyt.2014.11.005. Epub 2015 Jan 6.

PMID:
25573333
37.

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G.

J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2015 May 1;33(13):1519.

PMID:
25547501
38.

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M, Wermke M, Feldmann A, Bachmann M, Ehninger G, Oelschlägel U.

Blood Cancer J. 2014 Jun 13;4:e218. doi: 10.1038/bcj.2014.39.

39.

A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells.

Cartellieri M, Koristka S, Arndt C, Feldmann A, Stamova S, von Bonin M, Töpfer K, Krüger T, Geib M, Michalk I, Temme A, Bornhäuser M, Lindemann D, Ehninger G, Bachmann MP.

PLoS One. 2014 Apr 3;9(4):e93745. doi: 10.1371/journal.pone.0093745. eCollection 2014.

40.

Concise review: the bone marrow niche as a target of graft versus host disease.

von Bonin M, Bornhäuser M.

Stem Cells. 2014 Jun;32(6):1420-8. doi: 10.1002/stem.1691. Review.

41.

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity.

Cartellieri M, Arndt C, Feldmann A, von Bonin M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M.

Oncoimmunology. 2013 Dec 1;2(12):e26770. Epub 2013 Oct 22.

42.

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.

Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M.

Leukemia. 2014 Jan;28(1):59-69. doi: 10.1038/leu.2013.243. Epub 2013 Aug 20.

PMID:
23958923
43.

Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments.

Prewitz MC, Seib FP, von Bonin M, Friedrichs J, Stißel A, Niehage C, Müller K, Anastassiadis K, Waskow C, Hoflack B, Bornhäuser M, Werner C.

Nat Methods. 2013 Aug;10(8):788-94. doi: 10.1038/nmeth.2523. Epub 2013 Jun 23.

PMID:
23793238
44.

In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice.

von Bonin M, Wermke M, Cosgun KN, Thiede C, Bornhauser M, Wagemaker G, Waskow C.

PLoS One. 2013 Apr 9;8(4):e60680. doi: 10.1371/journal.pone.0060680. Print 2013.

45.

Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.

Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I, Stamova S, Bornhäuser M, Schmitz M, Ehninger G, Bachmann M.

Leukemia. 2013 Apr;27(4):964-7. doi: 10.1038/leu.2013.18. Epub 2013 Jan 17. No abstract available.

PMID:
23325142
46.

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.

Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schönefeldt C, Mair S, Plodeck V, Laniado M, Weiss G, Schetelig J, Ehninger G, Theurl I, Bornhäuser M, Platzbecker U.

Clin Cancer Res. 2012 Dec 1;18(23):6460-8. doi: 10.1158/1078-0432.CCR-12-1683. Epub 2012 Sep 18.

47.

Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.

Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, Wehner R, Schmitz M, Bornhäuser M, von Bonin M, Ehninger G, Bartsch H, Bachmann M.

Anal Biochem. 2012 Apr 15;423(2):261-8. doi: 10.1016/j.ab.2011.12.042. Epub 2012 Jan 4.

PMID:
22274538
48.

Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.

Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H, Bippes CC, Wehner R, Schmitz M, von Bonin M, Bornhäuser M, Ehninger G, Bachmann M.

Mol Immunol. 2011 Dec;49(3):474-82. doi: 10.1016/j.molimm.2011.09.019. Epub 2011 Oct 19.

PMID:
22014687
49.

Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.

Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, Aulitzky W, Bodenstein H, Tischler HJ, Stuhlmann R, Schuler U, Stölzel F, von Bonin M, Wandt H, Schäfer-Eckart K, Schaich M, Ehninger G.

J Clin Oncol. 2011 Jul 10;29(20):2758-65. doi: 10.1200/JCO.2010.32.8500. Epub 2011 May 31.

PMID:
21632498
50.

Hip pain in medulloblastoma as first symptom of extraneural relapse.

Sockel K, Ordemann R, von Bonin M, Jahn S, Prange-Krex G, Ehninger G, Kroschinsky F.

Onkologie. 2011;34(4):196-8. doi: 10.1159/000327002. Epub 2011 Mar 23. No abstract available.

PMID:
21447979

Supplemental Content

Loading ...
Support Center